

Luis Escribano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11169898/publications.pdf>

Version: 2024-02-01

90
papers

7,981
citations

66250

44
h-index

62345

84
g-index

107
all docs

107
docs citations

107
times ranked

3618
citing authors

#	ARTICLE	IF	CITATIONS
1	Mastocytosis presenting with mast cellâ€mediator releaseâ€associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features. <i>Clinical and Translational Allergy</i> , 2022, 12, e12132.	1.4	11
2	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768.	4.6	107
3	Frequency of clonal mast cell diseases among patients presenting with anaphylaxis: A prospective study in 178 patients from 5 tertiary centers in Spain. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2924-2926.e1.	2.0	7
4	Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 552.	1.8	9
5	Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 880-893.	1.5	50
6	Impact of somatic and germline mutations on the outcome of systemic mastocytosis. <i>Blood Advances</i> , 2018, 2, 2814-2828.	2.5	42
7	<i>KIT</i> D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2018, 2018, 1-16.	0.3	2
8	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.4	210
9	Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 1988-1991.	0.2	5
10	Systemic mastocytosis with <i>KIT</i> V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome. <i>Allergy, Asthma and Clinical Immunology</i> , 2017, 13, 21.	0.9	5
11	Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 <i>KIT</i> mutations and review of the literature. <i>Oncotarget</i> , 2017, 8, 68950-68963.	0.8	83
12	<i>KIT</i> D816Vâ€mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. <i>Blood</i> , 2016, 127, 761-768.	0.6	33
13	Diagnosis and classification of mastocytosis in nonâ€specialized <i>versus</i> reference centres: a Spanish Network on Mastocytosis (<i>REMA</i>) study on 122 patients. <i>British Journal of Haematology</i> , 2016, 172, 56-63.	1.2	15
14	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 35-45.	1.5	289
15	Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 168-178.e1.	1.5	72
16	Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes. <i>F1000Research</i> , 2016, 5, 2666.	0.8	17
17	The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. <i>Journal of Leukocyte Biology</i> , 2015, 97, 49-59.	1.5	47
18	Detection of the <i>KIT</i> D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. <i>Modern Pathology</i> , 2015, 28, 1138-1149.	2.9	88

#	ARTICLE	IF	CITATIONS
19	Systemic mastocytosis presenting as IgE-mediated food-induced anaphylaxis: A report of two cases. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 456-458.	2.0	11
20	Management of Anesthesia in Adult and Pediatric Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) Based on 726 Anesthetic Procedures. <i>International Archives of Allergy and Immunology</i> , 2015, 167, 47-56.	0.9	66
21	Response to celecoxib in a patient with indolent systemic mastocytosis presenting with intractable diarrhea. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 456-457.	0.5	3
22	Management of adult mastocytosis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 321-336.	0.5	4
23	Mastocytosis, Kounis syndrome and medical emergencies. <i>Internal and Emergency Medicine</i> , 2014, 9, 489-490.	1.0	1
24	Bone Involvement and Osteoporosis in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 383-396.	0.7	72
25	Flow Cytometry in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 297-313.	0.7	14
26	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 520-528.e5.	1.5	118
27	Identification and Immunophenotypic Characterization of Normal and Pathological Mast Cells. <i>Methods in Molecular Biology</i> , 2014, 1192, 205-226.	0.4	5
28	CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. <i>Histopathology</i> , 2013, 63, 780-787.	1.6	77
29	Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1213-1224.e4.	1.5	30
30	Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 614-615.	1.5	41
31	Venom Immunotherapy in Patients with Clonal Mast CELL Disorders: Efficacy, Safety and Practical Considerations. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB25.	1.5	58
32	Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 111, 425-426.	0.5	33
33	Venom Immunotherapy in Patients with Clonal Mast Cell Disorders: Efficacy, Safety, and Practical Considerations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2013, 1, 474-478.	2.0	85
34	Flow Cytometry Criteria for Systemic Mastocytosis: Bone Marrow Mast Cell Counts Do Not Always Count. <i>American Journal of Clinical Pathology</i> , 2013, 139, 404-406.	0.4	6
35	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	0.6	122
36	Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome. <i>PLoS ONE</i> , 2013, 8, e76116.	1.1	29

#	ARTICLE	IF	CITATIONS
37	Childhood mastocytosis. <i>Current Opinion in Pediatrics</i> , 2012, 24, 480-486.	1.0	47
38	Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2012, 30, e126-e129.	0.8	59
39	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 215-225.	0.9	513
40	Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. <i>Modern Pathology</i> , 2012, 25, 516-521.	2.9	55
41	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 807-814.	1.0	33
42	Diagnosis of Adult Mastocytosis: Role for Bone Marrow Analysis. , 2012, , 388-398.		6
43	Evaluation of the WHO criteria for the classification of patients with mastocytosis. <i>Modern Pathology</i> , 2011, 24, 1157-1168.	2.9	89
44	Diagnosis and Treatment of Cutaneous Mastocytosis in Children. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 259-270.	3.3	162
45	Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis. <i>Haematologica</i> , 2011, 96, e26-e26.	1.7	4
46	Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. <i>Immunotherapy</i> , 2011, 3, 637-651.	1.0	46
47	Dermoscopic Features of Skin Lesions in Patients With Mastocytosis. <i>Archives of Dermatology</i> , 2011, 147, 932.	1.7	72
48	Immunophenotypic Characterization of Bone Marrow Mast Cells in Mastocytosis and Other Mast Cell Disorders. <i>Methods in Cell Biology</i> , 2011, 103, 333-359.	0.5	36
49	Anaphylaxis in Mastocytosis. , 2011, , 257-269.		4
50	Las mastocitosis en el siglo XXI. <i>Piel</i> , 2010, 25, 177-178.	0.0	1
51	Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 719-726.e4.	1.5	128
52	Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1269-1278.e2.	1.5	263
53	Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 514-521.	1.5	252
54	STI571 (Glivec®) affects histamine release and intracellular pH after alkalisation in HMCs. <i>Journal of Cellular Biochemistry</i> , 2008, 103, 865-876.	1.2	7

#	ARTICLE	IF	CITATIONS
55	Influence of the tyrosine kinase inhibitors STI571 (Glivec®), lavendustin A and genistein on human mast cell line (HMC-1) activation. <i>Journal of Cellular Biochemistry</i> , 2008, 103, 1076-1088.	1.2	7
56	Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 519-526.	1.5	117
57	Generation of Anaphylatoxins by Human β -Tryptase from C3, C4, and C5. <i>Journal of Immunology</i> , 2008, 180, 6307-6316.	0.4	92
58	Recent advances in the understanding of mastocytosis: the role of KIT mutations. <i>British Journal of Haematology</i> , 2007, 138, 12-30.	1.2	205
59	Flow Cytometric Analysis of Normal and Neoplastic Mast Cells: Role in Diagnosis and Follow-Up of Mast Cell Disease. <i>Immunology and Allergy Clinics of North America</i> , 2006, 26, 535-547.	0.7	47
60	KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. <i>Blood</i> , 2006, 108, 2366-2372.	0.6	447
61	Urticaria pigmentosa and mastocytosis: The role of immunophenotyping in diagnosis and determining response to treatment. <i>Current Allergy and Asthma Reports</i> , 2006, 6, 282-288.	2.4	27
62	Calcium-pH Crosstalks in the human mast cell line HMC-1: Intracellular alkalinization activates calcium extrusion through the plasma membrane Ca^{2+} -ATPase. <i>Journal of Cellular Biochemistry</i> , 2006, 99, 1397-1408.	1.2	6
63	Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis. <i>Inflammation and Allergy: Drug Targets</i> , 2006, 5, 61-77.	1.8	76
64	Mastocytosis: Pathology, genetics, and current options for therapy. <i>Leukemia and Lymphoma</i> , 2005, 46, 35-48.	0.6	180
65	The European Competence Network on Mastocytosis. <i>Wiener Klinische Wochenschrift</i> , 2004, 116, 647-651.	1.0	23
66	Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). , 2004, 58B, 1-8.		130
67	Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 28-33.	1.5	20
68	Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. <i>Leukemia Research</i> , 2003, 27, 635-641.	0.4	217
69	Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. <i>British Journal of Haematology</i> , 2003, 120, 257-265.	1.2	44
70	One-Step Detection of c-kit Point Mutations Using Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping and Hybridization Probes. <i>American Journal of Pathology</i> , 2003, 162, 737-746.	1.9	194
71	Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease. <i>International Archives of Allergy and Immunology</i> , 2002, 128, 136-141.	0.9	184
72	Abnormal Expression of CD Antigens in Mastocytosis. <i>International Archives of Allergy and Immunology</i> , 2002, 127, 127-132.	0.9	43

#	ARTICLE	IF	CITATIONS
73	Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis. <i>Leukemia Research</i> , 2002, 26, 1043-1046.	0.4	25
74	Comparative Analysis of the Morphological, Cytochemical, Immunophenotypical, and Functional Characteristics of Normal Human Peripheral Blood Lineage ^{CD16+/HLA-DR+/CD14^{lo}} Cells, CD14+ Monocytes, and CD16 ⁺ Dendritic Cells. <i>Clinical Immunology</i> , 2001, 100, 325-338.	1.4	85
75	Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. <i>Blood</i> , 2001, 98, 3784-3792.	0.6	48
76	Diagnostic criteria and classification of mastocytosis: a consensus proposal. <i>Leukemia Research</i> , 2001, 25, 603-625.	0.4	1,020
77	Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. <i>Leukemia Research</i> , 2001, 25, 529-536.	0.4	206
78	Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. <i>Leukemia Research</i> , 2001, 25, 563-570.	0.4	124
79	Expression of high amounts of the CD117 molecule in a case of B-cell non-Hodgkin's lymphoma carrying the t(14:18) translocation. , 2000, 63, 226-229.		16
80	Immunophenotypic Analysis of Human Mast Cells by Flow Cytometry. <i>Current Protocols in Cytometry</i> , 2000, 12, Unit 6.6.	3.7	4
81	Immunophenotype of Bone Marrow Mast Cells in Indolent Systemic Mast Cell Disease in Adults. <i>Leukemia and Lymphoma</i> , 1999, 35, 227-235.	0.6	42
82	The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease. <i>British Journal of Haematology</i> , 1999, 106, 400-405.	1.2	36
83	Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. , 1999, 60, 191-195.		50
84	Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. , 1998, 34, 223-228.		34
85	Expression of the c-kit (CD117) Molecule in Normal and Malignant Hematopoiesis. <i>Leukemia and Lymphoma</i> , 1998, 30, 459-466.	0.6	113
86	Immunophenotypic Characterization of Human Bone Marrow Mast Cells. A Flow Cytometric Study of Normal and Pathological Bone Marrow Samples. <i>Analytical Cellular Pathology</i> , 1998, 16, 151-159.	2.1	72
87	Indolent Systemic Mast Cell Disease in Adults: Immunophenotypic Characterization of Bone Marrow Mast Cells and Its Diagnostic Implications. <i>Blood</i> , 1998, 91, 2731-2736.	0.6	232
88	Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. , 1997, 30, 98-102.		62
89	Amelanotic Bone Marrow Infiltration Secondary to Pigmented Malignant Melanoma. <i>Journal of Dermatology</i> , 1995, 22, 620-622.	0.6	6
90	Expression of lymphoid-associated antigens in mast cells: report of a case of systemic mast cell disease. <i>British Journal of Haematology</i> , 1995, 91, 941-943.	1.2	40